14 Dec 2006 07:00
Embargoed: 7.00hrs 14th December 2006
Akers Biosciences Inc. ("Akers" or the "Company") Expansion of Home Diagnostic Product Line
Thorofare, NJ, USA-December 14, 2006--Akers Biosciences Inc. is pleased to announce that it has obtained a sales and marketing license from a US diagnostic products company for the development, marketing and distribution of five additional diagnostic tests. These tests are intended to broaden Akers' home diagnostic product line, both in the United States and Europe. The products that were licensed include tests for pregnancy, fertility (ovulation), urinary tract infection, kidney/bladder function, and diabetes in urine. These tests will be marketed under the Company's "Check" trademark. All of the licensed products are FDA-cleared, and will be introduced into the marketplace in January, 2007. The Company will seek product approval for these products in the European Union.
These tests will complement the company's current home diagnostic product portfolio. Currently, the company's marketing efforts have focused on its Tri-Cholesterol Check, Breath Alcohol Check, and Free Radical Check products. Additional tests for prostate health, Chlamydia, and menopause are in product approval stages.
Akers intends to market these home diagnostic products through already established channels. The Company currently markets its home products to the Over-the Counter (OTC) market in the US through Alco Industries (Cranbury, NJ), and has recently established channels in the direct sales marketplace through its alliance with Pulse Marketing (Portland, OR). In addition, the company has begun marketing directly to consumers via the internet. In the UK and Europe, the company has partnered with Advanced Rapid Diagnostics (Manchester, UK).
Dr. Ray Akers, CEO of Akers Biosciences said, "The expansion of our home diagnostic product line represents a significant step in our strategy to penetrate the home healthcare market. With established relationships in three major retail channels, these additional products provide critical mass that should accelerate sales across all of our home diagnostic products."
Akers Biosciences
Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. Akers has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.
Enquiries:Dr. Ray Akers Chief Executive Officer, Akers Biosciences, 020 7917 9476 Inc. Paul Freedman 001 856 848 8698 Chief Financial Officer, Akers Biosciences, Inc. Bill Roberts CTC, Inc. 001 937 434 2700 Ben Simons Hansard Communications 020 7245 1100
AKERS BIOSCIENCES INC